JP2013530943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530943A5 JP2013530943A5 JP2013510360A JP2013510360A JP2013530943A5 JP 2013530943 A5 JP2013530943 A5 JP 2013530943A5 JP 2013510360 A JP2013510360 A JP 2013510360A JP 2013510360 A JP2013510360 A JP 2013510360A JP 2013530943 A5 JP2013530943 A5 JP 2013530943A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- peptide
- amino acids
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims description 146
- 150000001413 amino acids Chemical class 0.000 claims description 146
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 229940024606 amino acid Drugs 0.000 claims description 40
- 230000035772 mutation Effects 0.000 claims description 31
- 239000002671 adjuvant Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims description 11
- 239000003018 immunosuppressive agent Substances 0.000 claims description 11
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 4
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 4
- 101001024316 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 Proteins 0.000 claims description 4
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 4
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 101150053046 MYD88 gene Proteins 0.000 claims description 4
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 230000037455 tumor specific immune response Effects 0.000 claims description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 3
- 230000037433 frameshift Effects 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 230000037436 splice-site mutation Effects 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 102100035354 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 Human genes 0.000 claims description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016053473A JP6943545B2 (ja) | 2010-05-14 | 2016-03-17 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33486610P | 2010-05-14 | 2010-05-14 | |
| US61/334,866 | 2010-05-14 | ||
| PCT/US2011/036665 WO2011143656A2 (en) | 2010-05-14 | 2011-05-16 | Compositions and methods of identifying tumor specific neoantigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016053473A Division JP6943545B2 (ja) | 2010-05-14 | 2016-03-17 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530943A JP2013530943A (ja) | 2013-08-01 |
| JP2013530943A5 true JP2013530943A5 (enExample) | 2014-08-14 |
| JP5948319B2 JP5948319B2 (ja) | 2016-07-06 |
Family
ID=44915022
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510360A Active JP5948319B2 (ja) | 2010-05-14 | 2011-05-16 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2016053473A Active JP6943545B2 (ja) | 2010-05-14 | 2016-03-17 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2019071941A Active JP7008049B2 (ja) | 2010-05-14 | 2019-04-04 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2022000837A Pending JP2022044632A (ja) | 2010-05-14 | 2022-01-06 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2024021658A Pending JP2024045573A (ja) | 2010-05-14 | 2024-02-16 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016053473A Active JP6943545B2 (ja) | 2010-05-14 | 2016-03-17 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2019071941A Active JP7008049B2 (ja) | 2010-05-14 | 2019-04-04 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2022000837A Pending JP2022044632A (ja) | 2010-05-14 | 2022-01-06 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
| JP2024021658A Pending JP2024045573A (ja) | 2010-05-14 | 2024-02-16 | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US9115402B2 (enExample) |
| EP (4) | EP4623996A2 (enExample) |
| JP (5) | JP5948319B2 (enExample) |
| KR (4) | KR102447139B1 (enExample) |
| CN (2) | CN103180730B (enExample) |
| AU (1) | AU2011252795B2 (enExample) |
| BR (2) | BR112012029066A2 (enExample) |
| CA (2) | CA3197245A1 (enExample) |
| DK (1) | DK3023788T3 (enExample) |
| ES (3) | ES2788863T3 (enExample) |
| HU (1) | HUE049886T2 (enExample) |
| PL (1) | PL3023788T3 (enExample) |
| PT (1) | PT3023788T (enExample) |
| WO (1) | WO2011143656A2 (enExample) |
Families Citing this family (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| HUE049886T2 (hu) | 2010-05-14 | 2020-10-28 | Massachusetts Gen Hospital | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra |
| ES2746233T3 (es) * | 2011-05-24 | 2020-03-05 | Biontech Rna Pharmaceuticals Gmbh | Vacunas individualizadas para el cáncer |
| EP3892295B1 (en) * | 2011-05-24 | 2023-04-26 | BioNTech SE | Individualized vaccines for cancer |
| EP2757153B1 (en) * | 2011-08-02 | 2019-07-03 | The University of Tokyo | Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor |
| JP2014530013A (ja) * | 2011-09-29 | 2014-11-17 | トローバジーン インコーポレイテッド | Ｓｆ３ｂ１遺伝子における変異および慢性リンパ性白血病 |
| WO2013086464A1 (en) * | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| WO2013119947A1 (en) | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US10640535B2 (en) | 2012-05-25 | 2020-05-05 | Agenus Inc. | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies |
| MX364370B (es) * | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| AU2013308409A1 (en) * | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
| AU2013312529A1 (en) | 2012-09-05 | 2015-04-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
| EP2901341B1 (en) | 2012-09-28 | 2019-04-10 | The University of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| CA2892391C (en) | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| ES2739913T3 (es) | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
| EP2958588B1 (en) | 2013-02-22 | 2017-08-23 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| EP2970907B1 (en) | 2013-03-14 | 2020-01-01 | The Johns Hopkins University | Nanoscale artificial antigen presenting cells |
| JP6702855B2 (ja) * | 2013-04-07 | 2020-06-03 | ザ・ブロード・インスティテュート・インコーポレイテッド | 個別化された新生物ワクチンの組成物及び方法 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP4052724A1 (en) * | 2013-12-06 | 2022-09-07 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| BR112016014410A2 (pt) * | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| US20160326597A1 (en) * | 2014-01-02 | 2016-11-10 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| AU2015247727A1 (en) | 2014-04-15 | 2016-11-03 | University Of Virginia Patent Foundation | Isolated T cell receptors and methods of use therefor |
| CN107076762B (zh) * | 2014-09-10 | 2021-09-10 | 豪夫迈·罗氏有限公司 | 免疫原性突变体肽筛选平台 |
| AU2015315559A1 (en) * | 2014-09-10 | 2017-02-16 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| WO2016040900A1 (en) * | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| PT3193917T (pt) * | 2014-09-17 | 2021-10-20 | Io Biotech Aps | Composições de vacina compreendendo triptofano-2,3-dioxigenase ou fragmentos desta |
| SG11201702191YA (en) * | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| JP6599450B2 (ja) | 2014-10-02 | 2019-10-30 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| EP4029508A1 (en) * | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| WO2016174085A1 (en) * | 2015-04-27 | 2016-11-03 | Cancer Research Technology Limited | Method for treating cancer |
| CA2984234C (en) | 2015-05-01 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
| BR112017024797A2 (pt) * | 2015-05-20 | 2018-08-07 | The Broad Institute Inc. | neoantígenos partilhados |
| TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| EP3323070B1 (en) * | 2015-07-14 | 2024-05-08 | Personal Genome Diagnostics Inc. | Neoantigen analysis |
| EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| HK1258649A1 (zh) * | 2015-09-18 | 2019-11-15 | Baylor College Of Medicine | 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| KR102770755B1 (ko) * | 2015-10-12 | 2025-02-21 | 난토믹스, 엘엘씨 | 바이러스 네오에피토프 및 이의 용도 |
| EP3362103B1 (en) | 2015-10-12 | 2025-01-22 | Nantomics, LLC | Compositions and methods for viral cancer neoepitopes |
| AU2016339022B2 (en) * | 2015-10-12 | 2020-09-10 | Nantomics, Llc | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
| EP3362930A4 (en) * | 2015-10-12 | 2019-06-19 | Nantomics, LLC | SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS |
| US20180318409A1 (en) * | 2015-10-22 | 2018-11-08 | Modernatx, Inc. | Cancer vaccines |
| RU2743169C2 (ru) | 2015-11-06 | 2021-02-15 | Вентана Медикал Системз, Инк. | Репрезентативная диагностика |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| SG11201804957VA (en) * | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| CA3048193A1 (en) * | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| CN108701172A (zh) * | 2016-02-12 | 2018-10-23 | 南托米克斯有限责任公司 | 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点 |
| US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
| CN105720176A (zh) * | 2016-02-19 | 2016-06-29 | 京东方科技集团股份有限公司 | 一种胶囊量子点和发光二极管、制备方法及显示装置 |
| AU2017281126A1 (en) * | 2016-03-24 | 2018-10-04 | Nant Holdings Ip, Llc | Sequence arrangements and sequences for neoepitope presentation |
| WO2017177207A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| US20190062272A1 (en) * | 2016-04-13 | 2019-02-28 | Capten Therapeutics Inc. | Small molecules for immunogenic treatment of cancer |
| CA3028721A1 (en) | 2016-06-20 | 2017-12-28 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| HUE056660T2 (hu) * | 2016-07-20 | 2022-03-28 | BioNTech SE | A neoepitópok mint betegségspecifikus célpontok kiválasztása a fokozott hatékonyságú terápia számára |
| EP3493836A4 (en) * | 2016-08-02 | 2020-03-04 | Nantcell, Inc. | TRANSFECTION OF DENDRITIC CELLS AND RELATED METHODS |
| WO2018045249A1 (en) * | 2016-08-31 | 2018-03-08 | Medgenome, Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
| US10350280B2 (en) | 2016-08-31 | 2019-07-16 | Medgenome Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
| WO2018053242A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
| WO2018057447A1 (en) * | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
| WO2018071796A2 (en) * | 2016-10-13 | 2018-04-19 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| EP4338799A3 (en) * | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| US20190321481A1 (en) | 2016-11-11 | 2019-10-24 | Nantbio, Inc. | Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms |
| AU2017367696A1 (en) | 2016-12-01 | 2019-06-20 | Nant Holdings Ip, Llc | Tumor antigenicity processing and presentation |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP7731656B2 (ja) * | 2017-02-01 | 2025-09-01 | モデルナティエックス インコーポレイテッド | Ｒｎａ癌ワクチン |
| AU2018214556A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
| WO2018175505A1 (en) * | 2017-03-20 | 2018-09-27 | Genocea Biosciences, Inc. | Treatment methods |
| WO2018183544A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Method for identification of retained intron tumor neoantigens from patient transcriptome |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| CA3057715A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| CA3060569A1 (en) * | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| EP3615675A4 (en) | 2017-04-24 | 2021-03-03 | Nantcell, Inc. | TARGETED NEO-EPITOPIC VECTORS AND ASSOCIATED PROCESSES |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| EP3622068B1 (en) | 2017-05-10 | 2024-02-28 | The Broad Institute, Inc. | Methods for determination of mutations in single replication events |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| EP3630131B1 (en) * | 2017-06-02 | 2022-08-31 | Arizona Board of Regents on behalf of Arizona State University | A method to create personalized canine cancer vaccines |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| AU2018287159B2 (en) * | 2017-06-21 | 2025-01-16 | Transgene | Personalized vaccine |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| TWI832820B (zh) | 2017-07-21 | 2024-02-21 | 美商伯克利之光生命科技公司 | 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途 |
| WO2019023269A1 (en) | 2017-07-25 | 2019-01-31 | California Institute Of Technology | DISCOVERING TROGOCYTOSE MEDIATION EPITOPES |
| WO2019036043A2 (en) * | 2017-08-16 | 2019-02-21 | Medgenome Inc. | METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER |
| WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY |
| US20200362418A1 (en) * | 2017-10-02 | 2020-11-19 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
| RU2020115161A (ru) * | 2017-10-06 | 2021-11-08 | Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи | Днк моноклональных антител против ctla-4 для лечения и профилактики рака |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| JP7357613B2 (ja) * | 2017-11-06 | 2023-10-06 | ラディック インスティテュート フォア キャンサー リサーチ リミテッド | リンパ球の拡大方法 |
| EP3706770A4 (en) * | 2017-11-07 | 2021-10-27 | Nektar Therapeutics | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER |
| CN120519386A (zh) | 2017-11-08 | 2025-08-22 | 百欧恩泰美国公司 | T细胞制备组合物和方法 |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
| CN109682978B (zh) * | 2017-11-30 | 2020-07-03 | 四川康德赛医疗科技有限公司 | 一种肿瘤突变肽mhc亲和力预测方法及其应用 |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN111818943B (zh) | 2018-01-04 | 2024-09-03 | 伊科尼克治疗公司 | 抗组织因子抗体、抗体-药物缀合物及相关方法 |
| WO2019147921A1 (en) | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| US20210046177A1 (en) | 2018-01-26 | 2021-02-18 | Nantcell, Inc. | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy |
| CN108491689B (zh) * | 2018-02-01 | 2019-07-09 | 杭州纽安津生物科技有限公司 | 基于转录组的肿瘤新抗原鉴定方法 |
| KR20200127001A (ko) * | 2018-02-27 | 2020-11-09 | 그릿스톤 온콜로지, 인코포레이티드 | 범-대립유전자 모델을 갖는 신생항원 동정 |
| TW202012430A (zh) | 2018-04-26 | 2020-04-01 | 美商艾吉納斯公司 | 熱休克蛋白質－結合之胜肽組成物及其使用方法 |
| KR20210018321A (ko) * | 2018-05-25 | 2021-02-17 | 더 위스타 인스티튜트 | 종양 특이적 신생항원 및 이를 사용하는 방법 |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US12391736B2 (en) | 2018-07-26 | 2025-08-19 | Curevac Netherlands B.V. | Off-the-shelf cancer vaccines |
| WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
| IL321692A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for colorectal cancer |
| CA3106567A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| CA3106574A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
| CN112930569B (zh) | 2018-08-31 | 2025-10-03 | 夸登特健康公司 | 无细胞dna中的微卫星不稳定性检测 |
| GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
| TW202028224A (zh) * | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| TW202027761A (zh) | 2018-09-21 | 2020-08-01 | 美商柏克萊燈光有限公司 | 功能化孔盤、其製備方法及用途 |
| SG11202101965QA (en) | 2018-09-27 | 2021-04-29 | Vaccibody As | Method for selecting neoepitopes |
| EP3867353A4 (en) | 2018-10-18 | 2022-07-27 | Berkeley Lights, Inc. | PROTO-ANTIGEN PRESENTING SYNTHETIC SURFACES, ACTIVATED T-CELLS AND THEIR USES |
| US20200188435A1 (en) | 2018-11-08 | 2020-06-18 | Nexlmmune, Inc. | T cell compositions with improved phenotypic properties |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| CN109706065A (zh) * | 2018-12-29 | 2019-05-03 | 深圳裕策生物科技有限公司 | 肿瘤新生抗原负荷检测装置及存储介质 |
| MX2021010089A (es) | 2019-02-20 | 2021-12-10 | Rubius Therapeutics Inc | Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso. |
| CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
| US12427195B1 (en) * | 2019-03-11 | 2025-09-30 | La Jolla Institute For Immunology | Methods of neoantigen identification |
| WO2020185010A1 (ko) * | 2019-03-12 | 2020-09-17 | (주)신테카바이오 | 인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법 |
| EP3963335B1 (en) * | 2019-05-03 | 2024-08-21 | Epivax Therapeutics, Inc. | Neoantigens in cancer |
| EP3966323A4 (en) * | 2019-05-06 | 2024-04-24 | The Regents Of The University Of Michigan | TARGETED THERAPY |
| CN112011833B (zh) * | 2019-05-30 | 2024-04-26 | 上海桀蒙生物技术有限公司 | 筛选和分离肿瘤新生抗原的方法 |
| JP7457733B2 (ja) | 2019-05-30 | 2024-03-28 | グリットストーン バイオ インコーポレイテッド | 改変アデノウイルス |
| CN110322925B (zh) * | 2019-07-18 | 2021-09-03 | 杭州纽安津生物科技有限公司 | 一种预测融合基因产生新生抗原的方法 |
| CN110706747B (zh) * | 2019-09-17 | 2021-09-07 | 北京橡鑫生物科技有限公司 | 检测肿瘤新生抗原多肽的方法和装置 |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
| US20230212243A1 (en) * | 2020-05-12 | 2023-07-06 | Institut Curie | Neoantigenic Epitopes Associated with SF3B1 Mutations |
| US20230210968A1 (en) | 2020-06-11 | 2023-07-06 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| AU2021325081A1 (en) | 2020-08-13 | 2023-04-13 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| GB2613718A (en) * | 2020-08-31 | 2023-06-14 | World Biotech Regenerative Medical Group Ltd | Personalized immunogenic compositions and methods for producing and using same |
| KR102552632B1 (ko) * | 2020-11-06 | 2023-07-06 | 사회복지법인 삼성생명공익재단 | 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법 |
| EP4313129A4 (en) * | 2021-03-26 | 2025-05-14 | The Translational Genomics Research Institute | METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES |
| EP4330380A1 (en) | 2021-04-30 | 2024-03-06 | Tigen Pharma SA | Single vessel expansion of lymphocytes |
| WO2022251034A1 (en) * | 2021-05-27 | 2022-12-01 | Amazon Technologies, Inc. | Multicomponent chemical composition of a peptide-based neoantigen vaccine |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| CN115772564B (zh) * | 2021-09-08 | 2023-08-18 | 广州市基准医疗有限责任公司 | 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用 |
| EP4419716A1 (en) | 2021-10-21 | 2024-08-28 | CureVac Netherlands B.V. | Cancer neoantigens |
| CN116287158A (zh) * | 2021-12-08 | 2023-06-23 | 初源海生物科技(深圳)有限公司 | 一种新抗原鉴定和疗效预测方法 |
| WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| EP4598949A1 (en) | 2022-10-07 | 2025-08-13 | The General Hospital Corporation | Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4612276A1 (en) | 2022-11-02 | 2025-09-10 | Tigen Pharma SA | Expansion of lymphocytes |
| EP4474016A1 (en) | 2023-06-07 | 2024-12-11 | Julius-Maximilians-Universität Würzburg | Strategies to target extracellularly accessible ras protein |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US911A (en) | 1838-09-12 | Mode of fastening bedsteabs | ||
| US221332A (en) | 1879-11-04 | Improvement in fire-escapes | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| AU625013B2 (en) | 1989-11-03 | 1992-06-25 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| US5589406A (en) | 1993-07-30 | 1996-12-31 | Ag Technology Co., Ltd. | Method of making TFT display |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| KR20010083890A (ko) * | 1998-10-05 | 2001-09-03 | 에드워드 에이. 맥더모트, 주니어 | 암 관련 항원 및 그의 용도 |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| CA2374237A1 (en) * | 1999-05-06 | 2000-11-16 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
| US20060073150A1 (en) * | 2001-09-06 | 2006-04-06 | Mary Faris | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| AU5898400A (en) * | 1999-06-29 | 2001-01-31 | Epimmune, Inc. | Hla binding peptides and their uses |
| WO2001055177A2 (en) * | 2000-01-28 | 2001-08-02 | Statens Serum Institut | Methods to identify ctl epitopes of hiv |
| US20040071671A1 (en) * | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| PT1512014E (pt) | 2002-06-13 | 2009-11-10 | Merck Patent Gmbh | Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante |
| JP5156882B2 (ja) * | 2003-04-18 | 2013-03-06 | アイディーエム ファーマ，インコーポレイティド | Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物 |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| US20070112754A1 (en) | 2005-11-15 | 2007-05-17 | Honeywell International Inc. | Method and apparatus for identifying data of interest in a database |
| EP1994181A4 (en) | 2006-02-27 | 2010-05-19 | Univ Arizona | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| US9045556B2 (en) | 2007-02-07 | 2015-06-02 | Nec Corporation | Therapeutic agent for cancer |
| WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| US8598125B2 (en) | 2007-08-20 | 2013-12-03 | Onco Therapy Science, Inc. | CDCA1 peptide and pharmaceutical agent comprising the same |
| EP2238265A4 (en) | 2007-12-28 | 2012-01-18 | Wayne John Cancer Inst | USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA |
| US20110097312A1 (en) * | 2008-02-15 | 2011-04-28 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| WO2010033949A1 (en) * | 2008-09-22 | 2010-03-25 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| US8369279B2 (en) | 2010-03-10 | 2013-02-05 | Broadcom Corporation | Method and system for iterative multiple frequency hypothesis testing with cell-ID detection in an E-UTRA/LTE UE receiver |
| ES2742263T3 (es) | 2009-12-10 | 2020-02-13 | Merck Patent Gmbh | Composiciones farmacéuticas que comprenden oligopéptidos, preferiblemente cilengitida |
| WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| HUE049886T2 (hu) | 2010-05-14 | 2020-10-28 | Massachusetts Gen Hospital | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra |
| RU2621640C2 (ru) | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| AU2012206487A1 (en) | 2011-01-14 | 2013-07-18 | Genefirst Limited | Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence |
| KR20140057343A (ko) | 2011-08-18 | 2014-05-12 | 네스텍 소시에테아노님 | 대립형질 변이 검출을 위한 조성물 및 방법 |
| US20160130641A1 (en) | 2012-02-15 | 2016-05-12 | Janssen Diagnostics, Llc | Highly sensitive method for detecting low frequency mutations |
| IL318221A (en) | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
| WO2014150924A2 (en) | 2013-03-15 | 2014-09-25 | The Broad Institute, Inc. | Accurate typing of hla through exome sequencing |
| AU2015268982B2 (en) | 2014-06-05 | 2021-11-04 | Kling Biotherapeutics B.V. | Means and methods for determining T cell recognition |
| CA2957396C (en) | 2014-08-07 | 2021-03-09 | Evrykleia LIANIDOU | Method of determining pik3ca mutational status in a sample |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016183042A1 (en) | 2015-05-10 | 2016-11-17 | Quandx Inc. | Ultra sensitive probes for detection of nucleic acid |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
-
2011
- 2011-05-16 HU HUE15198284A patent/HUE049886T2/hu unknown
- 2011-05-16 ES ES15198284T patent/ES2788863T3/es active Active
- 2011-05-16 CA CA3197245A patent/CA3197245A1/en active Pending
- 2011-05-16 EP EP25172712.9A patent/EP4623996A2/en active Pending
- 2011-05-16 DK DK15198284.0T patent/DK3023788T3/da active
- 2011-05-16 KR KR1020217033374A patent/KR102447139B1/ko active Active
- 2011-05-16 CN CN201180034398.5A patent/CN103180730B/zh active Active
- 2011-05-16 BR BR112012029066-5A patent/BR112012029066A2/pt not_active Application Discontinuation
- 2011-05-16 WO PCT/US2011/036665 patent/WO2011143656A2/en not_active Ceased
- 2011-05-16 KR KR1020187026866A patent/KR102095670B1/ko active Active
- 2011-05-16 AU AU2011252795A patent/AU2011252795B2/en active Active
- 2011-05-16 JP JP2013510360A patent/JP5948319B2/ja active Active
- 2011-05-16 BR BR122021014039-1A patent/BR122021014039B1/pt active IP Right Grant
- 2011-05-16 US US13/108,610 patent/US9115402B2/en active Active
- 2011-05-16 PL PL15198284T patent/PL3023788T3/pl unknown
- 2011-05-16 EP EP19219395.1A patent/EP3699266B1/en active Active
- 2011-05-16 KR KR1020127032745A patent/KR102017898B1/ko active Active
- 2011-05-16 CA CA2797868A patent/CA2797868C/en active Active
- 2011-05-16 KR KR1020197034305A patent/KR102315754B1/ko active Active
- 2011-05-16 PT PT151982840T patent/PT3023788T/pt unknown
- 2011-05-16 ES ES19219395T patent/ES3038392T3/es active Active
- 2011-05-16 EP EP11781409.5A patent/EP2569633B1/en not_active Revoked
- 2011-05-16 EP EP15198284.0A patent/EP3023788B1/en active Active
- 2011-05-16 ES ES11781409.5T patent/ES2564841T3/es active Active
- 2011-05-16 CN CN201610051727.1A patent/CN105648056A/zh active Pending
-
2015
- 2015-07-08 US US14/794,449 patent/US20160008447A1/en not_active Abandoned
-
2016
- 2016-03-17 JP JP2016053473A patent/JP6943545B2/ja active Active
- 2016-06-20 US US15/187,174 patent/US20160331822A1/en not_active Abandoned
-
2017
- 2017-11-01 US US15/800,732 patent/US20180055922A1/en not_active Abandoned
-
2018
- 2018-11-05 US US16/181,098 patent/US20190060432A1/en not_active Abandoned
- 2018-11-13 US US16/188,737 patent/US10426824B1/en active Active
-
2019
- 2019-04-04 JP JP2019071941A patent/JP7008049B2/ja active Active
- 2019-04-11 US US16/381,791 patent/US20200069783A1/en active Pending
- 2019-07-31 US US16/528,195 patent/US20200016251A1/en active Pending
-
2022
- 2022-01-06 JP JP2022000837A patent/JP2022044632A/ja active Pending
-
2024
- 2024-02-16 JP JP2024021658A patent/JP2024045573A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530943A5 (enExample) | ||
| ES2544529T3 (es) | Nueva inmunoterapia contra diversos tumores como el cáncer gastrointestinal y gástrico | |
| JP6993402B2 (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| KR102451645B1 (ko) | 신세포암종(rcc) 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드와 골격의 조합 | |
| CN113906149A (zh) | 持久临床获益的癌症生物标志物 | |
| Hsia et al. | Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma | |
| JP2019511214A5 (enExample) | ||
| CA2960834A1 (en) | Immunogenic mutant peptide screening platform | |
| JP2022537054A (ja) | 多鎖キメラポリペプチドおよびその使用 | |
| US20180030422A1 (en) | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy | |
| US20210172961A1 (en) | Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer | |
| WO2020234875A2 (en) | Identification of recurrent mutated neopeptides | |
| CN104066746B (zh) | Topk肽及包含它们的疫苗 | |
| JP6518921B2 (ja) | Ｔｈ１細胞のＩＭＰ−３エピトープペプチドおよびこれを含有するワクチン | |
| CN114650842A (zh) | 抗tim-3抗体 | |
| CN102459314B (zh) | Ttk肽及包含它们的疫苗 | |
| CN103694315B (zh) | Cdc45l肽及包含它的疫苗 | |
| JP6905464B2 (ja) | 上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異 | |
| CN102939379B (zh) | Ect2肽及包含它们的疫苗 | |
| CN102884190B (zh) | Hjurp肽及包含它们的疫苗 | |
| CA3241225A1 (en) | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers | |
| Himuro et al. | Personalized peptide vaccines | |
| CN120858107A (zh) | 用于肺癌的新颖肿瘤抗原及其用途 | |
| TW202118780A (zh) | Ｉｉ類ｍｈｃ分子及其使用方法 | |
| KR20200111264A (ko) | 암 항원 펩티드 |